drugset / Trial / NCT00280436

Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia

NCT00280436

Phase 2 Completed 122 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.

Timeline

Start
2006-01
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule